Trans fatty acids
This article was originally published in The Tan Sheet
Executive Summary
FDA reopens until Jan. 19 comment period on prudence of listing trans fatty acids in "Nutrition Facts" labeling and whether terms "reduced trans fat" and "reduced saturated and trans fat" should be better defined in nutrient content claims for foods, including dietary supplements, according to recent Federal Register notice. Proposed rule was published by agency Nov. 17, 1999 (1"The Tan Sheet" Nov. 15, 1999, In Brief)
You may also be interested in...
Trans Fat Footnote Statement On Food, Supplement Labeling Proposed By FDA
FDA is seeking comments on the proposed use of a footnote statement on food and dietary supplement products containing trans fat that would advise consumers against excessive intake of the ingredient
Trans fatty acids
Food marketers would be required to disclose the trans fatty acids content of products in the "Nutrition Facts" panel under an FDA proposed rule expected to be published in the Nov. 17 Federal Register. The levels of trans fat also would be considered when attempting to meet the requirements for claims regarding "low saturated fat" and "reduced saturated fat," as well as "lean," "extra lean" and cholesterol claims. Products containing more than 4 g saturated and trans fat combined per serving additionally would be prohibited from making health claims, such as the approved claim for calcium and osteoporosis. The public comment period on the proposal will run for 90 days
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC